Clinical Research: Principal Investigator
2003-present - A randomized, placebo-controlled, double-masked, multicenter, phase III study of the effect of Visudyne therapy in minimally classic subfoveal choroidal neovascularization (CNV)secondary to age-related macular degeneration (AMD): Visudyne in Minimally Classic (VMC)
2003-present - Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema
2003-present - A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration
2003-present - Patient Registry for Visudyne Therapy
2001-present - A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)
Clinical Research: Sub-Investigator
2004-present - The standard care vs. corticosteroid for retinal vein occlusion. The SCORE study.
2004-present - An evaluation of efficacy and safety of posterior juxtascleral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in Study "A" or Study "B") at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
2003-present - An open-label, multi-center trial of the safety, tolerability and pharmacokinetics of 3 mg/eye intravitreal injections of pegaptanib sodium (Anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
2002-present - A phase II randomized, controlled, doubled-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula.
2001-present - A phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
